-
公开(公告)号：US20220356230A1
公开(公告)日：2022-11-10
申请号：US17207524
申请日：2021-03-19
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Robert Babb , Alina BAUM , Gang CHEN , Cindy GERSON , Johanna HANSEN , Tammy HUANG , Christos KYRATSOUS , Wen-Yi LEE , Marine MALBEC , Andrew MURPHY , William OLSON , Neil STAHL , George D. YANCOPOULOS
IPC: C07K16/10 , A61K45/06 , A61K39/395 , A61K39/15
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
-
2.发明公开公开(公告)号：US20240350625A1
公开(公告)日：2024-10-24
申请号：US18610188
申请日：2024-03-19
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Seblewongel ASRAT , Andre LIMNANDER , Jamie M. ORENGO , Andrew J. MURPHY , George D. YANCOPOULOS
IPC: A61K39/395 , A61K39/00 , A61P37/08
CPC classification number: A61K39/3955 , A61P37/08 , A61K2039/507
Abstract: The present disclosure provides methods for treating allergy comprising selecting a patient with an allergy and administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor (e.g., an anti-IL-4 receptor antibody or antigen-binding fragment thereof) in combination with a therapeutically effective amount of an agent that depletes plasma cells (e.g., an anti-BCMA/anti-CD3 bispecific antibody). In certain embodiments, a plasma cell ablating agent such as an anti-BCMA/anti-CD3 bispecific antibody ablates the plasma cells, including IgE+ plasma cells, while the IL-4/IL-13 pathway inhibitor prevents the generation of new IgE+ plasma cells, thus eliminating allergen-specific IgE in the patient.
-
公开(公告)号：US20180051066A1
公开(公告)日：2018-02-22
申请号：US15624845
申请日：2017-06-16
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Nicholas J. PAPADOPOULOS , Samuel DAVIS , George D. YANCOPOULOS
CPC classification number: C07K14/71 , A61K38/00 , C07H21/04 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30 , C12N15/09 , C12N15/10
Abstract: The present invention provides VEGF antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing VEGF activity is provided comprising a modified extracellular ligand binding domain of a VEGF receptor fused to a multimerizing component.
-
公开(公告)号：US20170202911A1
公开(公告)日：2017-07-20
申请号：US15471506
申请日：2017-03-28
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： George D. YANCOPOULOS
CPC classification number: A61K38/179 , A61K9/0048 , A61K2039/505 , C07K14/71 , C07K16/22 , C07K2319/30 , C07K2319/32
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
-
5.发明申请DIAGNOSTIC TESTS AND METHODS FOR ASSESSING SAFETY, EFFICACY OR OUTCOME OF ALLERGEN-SPECIFIC IMMUNOTHERAPY (SIT) 审中-公开用于评估过敏性免疫球蛋白（SIT）的安全性，有效性或成果的诊断试验和方法公开(公告)号：US20160223563A1
公开(公告)日：2016-08-04
申请号：US14913645
申请日：2014-08-22
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： George D. YANCOPOULOS , Jamie ORENGO
CPC classification number: G01N33/6854 , A61K49/0008 , G01N33/502 , G01N33/5088 , G01N2800/24 , G01N2800/52
Abstract: The present invention provides in vitro and in vivo diagnostic tests and methods for determining the safety, efficacy, or outcome of allergen-specific immunotherapy (SIT) in a patient. The present invention also provides for the measurement of allergen specific IgG and IgE in a patient tissue sample, or extract thereof, or in a biological fluid or blood sample, and determining whether the allergen-specific immunoglobulins contained in the patient sample(s), upon injection into an allergen-sensitized animal, will protect the animal following challenge with the allergen. The invention also provides methods for determining whether a patient suffering from an allergy is responsive to therapy with one or more therapeutic antibodies specific for the allergen.
Abstract translation: 本发明提供用于确定患者中变应原特异性免疫治疗（SIT）的安全性，功效或结果的体外和体内诊断测试和方法。 本发明还提供了患者组织样品或其提取物或生物液体或血液样品中变应原特异性IgG和IgE的测量，以及测定患者样品中包含的变应原特异性免疫球蛋白， 在注射过敏原敏化动物后，会在用过敏原攻击后保护动物。 本发明还提供了用于确定患有过敏的患者是否对一种或多种对变应原特异的治疗性抗体的治疗有反应的方法。
-
Patent Agency Ranking
公开(公告)号：US20240123030A1
公开(公告)日：2024-04-18
申请号：US18496472
申请日：2023-10-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： George D. YANCOPOULOS
CPC classification number: A61K38/179 , A61K9/0048 , C07K14/71 , C07K16/22 , A61K2039/505
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
-
公开(公告)号：US20230125469A1
公开(公告)日：2023-04-27
申请号：US17863864
申请日：2022-07-13
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Alina BAUM , Christos KYRATSOUS , George D. YANCOPOULOS
IPC: C07K16/10 , C12N15/85 , C07K14/005 , A61K39/42 , A61P31/14
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).
-
公开(公告)号：US20210163611A1
公开(公告)日：2021-06-03
申请号：US17064393
申请日：2020-10-06
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： Joel H. MARTIN , Tammy T. HUANG , Jeanette L. FAIRHURST , Nicholas J. PAPADOPOULOS , George D. YANCOPOULOS
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K39/00
Abstract: The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (lL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-lL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-lL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.
-
公开(公告)号：US20160101152A1
公开(公告)日：2016-04-14
申请号：US14972560
申请日：2015-12-17
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： George D. YANCOPOULOS
CPC classification number: A61K38/179 , A61K9/0048 , A61K2039/505 , C07K14/71 , C07K16/22 , C07K2319/30 , C07K2319/32
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
-
公开(公告)号：US20250152669A1
公开(公告)日：2025-05-15
申请号：US19027212
申请日：2025-01-17
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： George D. YANCOPOULOS
Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.017 seconds)
